Harvard Medical School
Boston, Massachusetts, United States
Dr. Hiroaki Wakimoto graduated Tokyo Medical and Dental University, Tokyo, Japan, to earn MD, and completed PhD after studying genetically modified cancer vaccines for brain tumors. His post-doc work at Dr. Chiocca’s laboratory at Massachusetts General Hospital (MGH) was on oncolytic herpes simplex virus. Since 2009, Dr. Wakimoto has been a faculty member of Neurosurgery at MGH, Harvard Medical School, and is currently an associate professor of the department. Dr. Wakimoto’s research interest is in preclinical modeling and development of oncolytic viruses for neuro-oncological diseases, gliomas and high grade meningiomas. Patient-derived malignant glioma cells established by his group have been widely used in laboratories across the globe. Dr. Wakimoto is currently serving as an editor in Cancers and on the editorial board of Journal of Neuro-Oncology and Molecular Therapy – Oncolytics.
